牛牛AI助理已提取核心訊息
Adial Pharmaceuticals, Inc. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its Form S-3 effective as of January 24, 2024, at 5:00 PM. This form is a registration statement that allows companies to issue various securities, including stocks and bonds, to the public. The effectiveness of this form indicates that Adial Pharmaceuticals has met all the necessary regulatory requirements to proceed with the issuance of securities.
Adial Pharmaceuticals, Inc. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its Form S-3 effective as of January 24, 2024, at 5:00 PM. This form is a registration statement that allows companies to issue various securities, including stocks and bonds, to the public. The effectiveness of this form indicates that Adial Pharmaceuticals has met all the necessary regulatory requirements to proceed with the issuance of securities.
Adial Pharmicals, Inc.取得了重要的里程碑，美國證券交易委員會（SEC）宣佈其S-3表格自2024年1月24日下午5點起生效。該表格是一份註冊聲明，允許公司向公衆發行各種證券，包括股票和債券。該表格的有效性表明，Adial Pharmicals已經滿足了進行證券發行的所有必要監管要求。
Adial Pharmicals, Inc.取得了重要的里程碑，美國證券交易委員會（SEC）宣佈其S-3表格自2024年1月24日下午5點起生效。該表格是一份註冊聲明，允許公司向公衆發行各種證券，包括股票和債券。該表格的有效性表明，Adial Pharmicals已經滿足了進行證券發行的所有必要監管要求。
有用
沒用